Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Intensity Therapeutics Earnings Call: Key Takeaways

Intensity Therapeutics is restarting Phase 3 and Phase 2 trials after funding-related pauses, but remains severely capital-constrained with only $8.5 million in cash, making future enrollment timelines entirely dependent on successful capital raises.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Mgmt ConfidenceEnthusiastic about clinical data but cautious, citing capital as restriction on speed.
Demand VisibilityHigh investigator interest; 32 sites with contracts, 30 more in negotiation.
Segment GrowthInvincible 3 (Sarcoma) and Invincible 4 (Breast Cancer) both resumed enrollment Q3.
New ClientsAdded new CROs for statistical analysis and central CT image reading.
Capex & DebtRaised $3.2M via ATM; $8.5M cash; $1M monthly burn expected Q4.
RegulatorySwitching to Choi density criteria for Phase 3; IDMB safety review Q1.
CommentaryManagement argues water-based drugs fail in tumors; their product is lipid-compatible.
New LaunchesInitiated new manufacturing batch of INT230-6; completion expected Q1 2027.

Growth

Net loss increased 33% to $3.5 million; R&D expenses rose 56% to $2.4 million.

Outlook

Targeting completion of Invincible 4 enrollment by end of 2027, pending incremental funding.

Risks

Management pivoted on specific enrollment numbers, admitting capital is the primary gating factor for speed.

Source

The company's earnings call, NASDAQ: INTS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Intensity Therapeutics, Inc.: key numbers

Share price
$3.07Close, Nov 16
Market cap
$10.1M
Shares outstanding
3.3MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Intensity Therapeutics, Inc.

All →
7:55 AM ET 8-K
Business Update

Intensity Therapeutics Business Update

Intensity Therapeutics reported its Q3 2026 financial results and provided an operational update on its clinical pipeline, including the resumption of patient enrollment in the Phase 3 INVINCIBLE-3 soft tissue sarcoma study and the Phase 2 INVINCIBLE-4 triple-negative breast cancer study. The company ended the quarter with $8.5 million in cash and cash equivalents.

7:40 AM ET 10-Q
Financial Results ▶ Call

Intensity Therapeutics Q3 2026 Results: Net Loss of $3.54M, Loss Widens

Intensity Therapeutics reported a net loss of $9.0 million for the nine months ended September 30, 2026, compared to $8.6 million in the prior year period. The company's cash position decreased to $8.5 million from $11.9 million at year-end 2025, primarily due to ongoing research and development expenses for its lead drug candidate, INT230-6.

Key figure
Net loss $3.54M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.